Document:

<PAGE>

                                                                    EXHIBIT 10.6

                                                                 January 4, 2005

                                LICENSE AGREEMENT

      This Agreement is between ImaRx Therapeutics, a corporation of the State
of Delaware, having a principal place of business at 1635 E. 18th St., Tucson,
AZ 85718 (hereinafter referred to as "IMARX") and Dr. med. Reinhard Schlief,
(hereinafter "DR. SCHLIEF"), having an address at Neue Strasse 21, 14163 Berlin,
Germany.

                                   WITNESSETH:

      WHEREAS, DR. SCHLIEF owns certain intellectual property; and

      WHEREAS, IMARX is desirous of obtaining a license under the intellectual
property and wishes to acquire a license in order to utilize or otherwise
commercialize the intellectual property; and

      NOW, THEREFORE, in consideration of the premises and the mutual promises
and covenants hereinafter set forth, the parties hereby agree as follows

                             ARTICLE 1 - DEFINITIONS

      1.1 "PATENT RIGHTS" shall mean the U.S. patent 5,380,411, and assigned to
DR. SCHLIEF, entitled "Ultrasound or Shock Wave Work Process and Preparation for
Carrying Out Same" and the invention disclosed and claimed therein, and all
continuations, divisions, and reissues based thereof, and any corresponding
foreign patent applications (including Japan and EU countries), and any patents,
patents of addition, or other equivalent foreign patent rights issuing, granted
or registered thereon.

      1.2 "LICENSED PRODUCT(S)" shall mean products or services using a method
covered by a VALID CLAIM, on a country-by-country basis, that if made, used,
sold, imported or offered for sale would constitute, but for the license granted
to IMARX pursuant to this Agreement, an infringement of a VALID CLAIM
(infringement shall include, but is not limited to, direct, contributory, or
inducement to infringe).

<PAGE>

                                       2                         January 4, 2005

      1.3 "NET SALES" shall mean gross sales revenues received by IMARX,
AFFILIATED COMPANY and IMARX's sublicensees from the sale of LICENSED PRODUCT(S)
less trade discounts allowed, refunds, returns and recalls, and sales taxes. In
the event that IMARX, AFFILIATED COMPANY or IMARX's sublicensee sells a LICENSED
PRODUCT(S) in combination with other ingredients or substances or as part of a
kit, the NET SALES for purposes of royalty payments shall be based on calculated
as follows:

      (a)   If all LICENSED PRODUCTS and Other Items contained in the
            combination are available separately, the NET SALES for purposes of
            royalty payments will be calculated by multiplying the NET SALES of
            the combination by the fraction A/A+B, where A is the separately
            available price of all LICENSED PRODUCTS in the combination, and B
            is the separately available price for all Other Items in the
            combination.

      (b)   If the combination includes Other Items which are not sold
            separately (but all LICENSED PRODUCTS contained in the combination
            are available separately), the NET SALES for purposes of royalty
            payments will be calculated by multiplying the NET SALES of the
            combination by A/C, where A is as defined above and C is the
            invoiced price of the combination.

      (c)   If the LICENSED PRODUCTS contained in the combination are not sold
            separately, the NET SALES for such combination shall be NET SALES of
            such combination as defined in the first sentence of this Paragraph
            1.3. However, the parties agree to negotiate a reduction in the
            royalty rate to reflect the fair value that the LICENSED PRODUCT
            attributed to the overall product sold, but in no event shall the
            royalty rates be reduced by greater than fifty percent (50%).

The term "Other Items" does not include solvents, diluents, carriers,
excipients, buffers or the like used in formulating a product.

      1.4 "VALID CLAIM" shall mean a claim of an issued patent in PATENT RIGHTS
which has not lapsed or become abandoned or been declared invalid or
unenforceable by a court of competent jurisdiction or an administrative agency
from which no appeal can be or is taken.

      1.5 "LICENSED FIELD" shall mean all fields.

      1.6 "AFFILIATED COMPANY" or "AFFILIATED COMPANIES" shall mean any
corporation, company, partnership, joint venture or other entity which controls,
is controlled by or is under common control with IMARX. For purposes of this
Paragraph 1.6, control shall mean the

<PAGE>

                                       3                        January 4, 2005

direct or indirect ownership of at least fifty percent (50%).

      1.7 "EXCLUSIVE LICENSE" shall mean a grant by DR. SCHLIEF to IMARX of its
entire right and interest in the PATENT RIGHTS.

      1.8 "EFFECTIVE DATE" of this License Agreement shall mean the date the
last party hereto has executed this Agreement.

                               ARTICLE 2 - GRANTS

      2.1 Subject to the terms and conditions of this Agreement, DR. SCHLIEF
hereby grants to IMARX an EXCLUSIVE LICENSE to make, have made, use, sell and
have sold the LICENSED PRODUCT(S) in the United States and worldwide under the
PATENT RIGHTS in the LICENSED FIELD.

      2.2   IMARX may sublicense others under this Agreement and any sublicense
            shall be consistent with the terms of this Agreement.

      2.3   If for any reason other than being sold to another company IMARX
            ceases to exist, then patent rights shall return to DR. SCHLIEF. In
            the event that IMARX is sold to another company, the rights and
            responsibilities assigned to IMARX in this Agreement will be
            transferred to the company.

                         ARTICLE 3 - PATENT INFRINGEMENT

      3.1 Each party will notify the other promptly in writing when any
infringement by another is uncovered or suspected.

      3.2 IMARX shall have the right to enforce any patent within PATENT RIGHTS
in the LICENSED FIELD against any infringement or alleged infringement thereof,
and shall keep DR. SCHLIEF informed as to the status thereof. IMARX may, in its
sole judgment and at its own expense, institute suit against any such infringer
or alleged infringer and control, settle, and defend

<PAGE>

                                       4                        January 4, 2005

such suit in a manner consistent with the terms and provisions hereof and
recover, for its account, any damages, awards or settlements resulting
therefrom.

      3.3 If IMARX elects not to enforce any patent within the PATENT RIGHTS,
then it shall so notify DR. SCHLIEF in writing within six (6) months of
receiving notice that an infringement exists, and DR. SCHLIEF may, in his sole
judgment and at its own expense, take steps to enforce any patent and control,
settle, and defend such suit in a manner consistent with the terms and
provisions hereof, and recover, for his own account, any damages, awards or
settlements resulting therefrom.

                    ARTICLE 4 - PAYMENTS, ROYALTY AND EQUITY

      4.1 IMARX will reimburse DR. SCHLIEF for certain past out-of-pocket costs
associated with PATENT RIGHTS including but not limited to maintenance fees and
patent transfer fees up to the amount of $15,000.00 US Dollars. IMARX shall
reimburse DR. SCHLIEF within thirty (30) days of receipt of invoice from DR.
SCHLIEF. Such invoice shall provide copies of documentation from patent
attorney's and patent offices or other acceptable documentation detailing the
out-of-pocket patent costs incurred by DR. SCHLIEF. IMARX shall also reimburse
future incurred expenses as detailed in Paragraph 5.1.

      4.2 In partial consideration for the license granted herein, IMARX grants
DR.SCHLEIF warrants to purchase 20,000 shares of IMARX common stock pursuant to
the COMMON STOCK WARRANT attached as Exhibit A.

      4.3 IMARX shall pay to DR. SCHLIEF, as a running royalty, for each
LICENSED PRODUCT sold by IMARX or AFFILIATED COMPANIES, two percent (2%) of NET
SALES for the term of this Agreement. Should IMARX be required to pay running
royalties on any patent rights not licensed hereunder ("Other Royalties") in
order to make, use or sell a particular LICENSED PRODUCT, IMARX shall be
entitled to credit half (50%) of such Other Royalties against the running
royalty due, provided that the running royalties shall not be reduced below
fifty percent (50%) of those that would otherwise be due DR. SCHLIEF for that
LICENSED PRODUCT.

      Such payments shall be made twice per year as provided in Paragraph 4.5.

<PAGE>

                                       5                        January 4, 2005

      4.4 In the event IMARX grants a sublicense of rights to a third party
under this Agreement, IMARX shall pay DR. SCHLIEF three percent (3%) of any
milestone payments or running royalties received by IMARX, for sublicensing
PATENT RIGHTS. Research support to fund development of a LICENSED PRODUCT,
patent cost or other out-of-pocket reimbursements or equity investments made at
fair market value are excluded, however DR. SCHLIEF shall receive three percent
(3%) of the excess above fair market value of any equity investments. If any
Other Rights (Other Rights are rights other than PATENT RIGHTS that are owned or
controlled by IMARX) are conveyed under a sublicense, the percentage owed to DR.
SCHLIEF shall be based upon the value of the contribution of PATENT RIGHTS to
the overall value of all rights being sublicensed to the third party. The
determination of value of right shall be made by an independent agent of
national stature who is mutually agreeable to both parties and the costs of such
valuation shall be borne equally between IMARX and DR. SCHLIEF.

      4.5 IMARX shall provide to DR. SCHLIEF within sixty (60) days of the end
of each June after the a first commercial sale of a LICENSED PRODUCT, a written
report of the amount of LICENSED PRODUCTS sold, the total NET SALES of each
LICENSED PRODUCTS, and the running royalties due to DR. SCHLIEF as a result of
NET SALES by IMARX, AFFILIATED COMPANIES and sublicensees thereof. Payment of
any such royalties due shall accompany such report.

      4.6 IMARX shall make and retain, for a period of three (3) years following
the period of each report required by Paragraph 4.5, true and accurate records,
files and books of account containing all the data reasonably required for the
full computation and verification of sales and other information required in
Paragraph 4.5. Such books and records shall be in accordance with generally
accepted accounting principles consistently applied. IMARX shall permit the
inspection and copying of such records, files and books of account by an
independent accountant of nationally recognized stature selected by DR. SCHLIEF
and acceptable to IMARX. Such inspection shall be during regular business hours
and upon ten (10) business days' written notice to IMARX. Such inspection shall
not be made more than once each calendar year. All costs of such inspection and
copying shall be paid by DR. SCHLIEF, provided that if any such inspection shall
reveal that an error has been made in the amount equal to ten percent (10%) or
more of such payment, such costs shall be borne by IMARX. IMARX shall include in
any agreement with its AFFILIATED COMPANIES or its sublicensees which permits
such party to make, use or sell the LICENSED PRODUCT(S) a

<PAGE>

                                       6                        January 4, 2005

provision requiring such party to retain records of sales of LICENSED PRODUCT(S)
and other information as required in Paragraph 4.5 and permit DR. SCHLIEF's
agents to inspect such records as required by this Paragraph 4.6.

      4.7 All payments under this Agreement shall be made in U.S. Dollars.

             ARTICLE 5 - PATENT RIGHTS AND CONFIDENTIAL INFORMATION

      5.1 DR. SCHLIEF shall notify IMARX of any patent related costs due at
least thirty (30) days prior to any payment being due. IMARX shall promptly
notify DR. SCHIEF in writing of its desire to maintain such patent (Authorized
Expense) and shall reimburse DR. SCHLIEF upon receipt of an invoice for such
approved expense. Title to all such patents shall reside in DR. SCHLIEF. In any
country where IMARX elects not to pay expenses associated with maintaining a
patent, DR.SCHLIEF may maintain such patent at his own expense and for his own
exclusive benefit and IMARX thereafter shall not be licensed under, or owe
monies for, such patent right.

      5.2 IMARX agrees that all packaging containing individual LICENSED
PRODUCT(S) sold by IMARX, AFFILIATED COMPANIES and sublicensees of IMARX will be
marked with the number of the applicable patent(s) licensed hereunder in
accordance with each country's patent laws.

      5.3 If necessary, the parties will exchange information which they
consider to be confidential. The recipient of such information agrees to accept
the disclosure of said information which is marked as confidential at the time
it is sent to the recipient, and to employ all reasonable efforts to maintain
the information secret and confidential, such efforts to be no less than the
degree of care employed by the recipient to preserve and safeguard its own
confidential information. The information shall not be disclosed or revealed to
anyone except employees of the recipient who have a need to know the information
and who have entered into a secrecy agreement with the recipient under which
such employees are required to maintain confidential the proprietary information
of the recipient and such employees shall be advised by the recipient of the
confidential nature of the information and that the information shall be treated
accordingly. The recipient's obligations under this Paragraph 5.3 shall not
extend to any part of the information:

      a. that can be demonstrated to have been in the public domain or publicly
      known and

<PAGE>

                                       7                         January 4, 2005

      readily available to the trade or the public prior to the date of the
      disclosure; or

      b. that can be demonstrated, from written records to have been in the
      recipient's possession or readily available to the recipient from another
      source not under obligation of secrecy to the disclosing party prior to
      the disclosure; or

      c. that becomes part of the public domain or publicly known by publication
      or otherwise, not due to any unauthorized act by the recipient; or

      d. that is demonstrated from written records to have been developed by or
      for the receiving party without reference to confidential information
      disclosed by the disclosing party.

      e. that is required to be disclosed by law, government regulation or court
      order.

The obligations of this Paragraph 5.3 shall also apply to AFFILIATED COMPANIES
and/or sublicensees provided such information by IMARX. DR. SCHLIEF, the
IMARX's, AFFILIATED COMPANIES, and sublicensees' obligations under this
Paragraph 5.3 shall extend until five (5) years after the termination of this
Agreement.

                        ARTICLE 6 - TERM AND TERMINATION

      6.1 This Agreement shall expire in each country on the date of expiration
of the last to expire patent included within PATENT RIGHTS in that country.

      6.2 Upon breach or default of any of the terms and conditions of this
Agreement, the defaulting party shall be given written notice of such default in
writing and a period of sixty (60) days after receipt of such notice to correct
the default or breach. If the default or breach is not corrected within said
sixty (60) day period, the party not in default shall have the right to
terminate this Agreement.

      6.3 IMARX may terminate this Agreement and the license granted herein, for
any reason, upon giving DR. SCHLIEF sixty (60) days written notice.

<PAGE>

                                       8                         January 4, 2005

      6.4 Termination shall not affect DR. SCHLIEF's right to recover unpaid
royalties or fees or reimbursement for Authorized Expense incurred pursuant to
Paragraph 5.1 prior to termination. Upon termination all rights in and to the
licensed technology shall revert to DR. SCHLIEF at no cost to ImaRx.

                            ARTICLE 7 - MISCELLANEOUS

7.1 All notices pertaining to this Agreement shall be (a) delivered in person,
or (b) mailed certified mail return receipt requested, or (c) faxed to other
party if the sender has evidence of successful transmission and if the sender
promptly sends the original by ordinary mail, in any event to the following
addresses:

FOR IMARX:            Jean Carlyle
                      CFO
                      ImaRx Therapeutics Inc.
                      1635 E. 18th Street
                      Tucson, Arizona 85719

FOR DR. SCHLIEF:      Dr. med. Reinhard Schlief
                      Neue Strasse 21
                      14163 Berlin
                      Germany

      7.2 All written royalty and other payments, and any other related
correspondence shall be in writing and sent to:

FOR DR. SCHLIEF:      Dr. med. Reinhard Schlief
                      Neue Strasse 21
                      14163 Berlin
                      Germany

or such other addressee which DR. SCHLIEF may designate in writing from time to
time. Checks are to be made payable to "Dr. med. Reinhard Schlief". Wire
transfers may be made through:

<PAGE>

                                       9                        January 4, 2005

      7.3 This Agreement is binding upon and shall inure to the benefit of DR.
SCHLIEF, his successors and assignees and shall not be assignable to another
party without the written consent of DR. SCHLIEF, which consent shall not be
unreasonably withheld, except that IMARX shall have the right to assign this
Agreement to another party without the consent of DR. SCHLIEF in the case of the
sale or transfer by IMARX of all, or substantially all, of its assets relating
to the LICENSED PRODUCT to that party.

      7.4 In the event that any one or more of the provisions of this Agreement
should for any reason be held by any court or authority having jurisdiction over
this Agreement, or over any of the parties hereto to be invalid, illegal or
unenforceable, such provision or provisions shall be reformed to approximate as
nearly as possible the intent of the parties, and if unreformable, shall be
divisible and deleted in such jurisdictions; elsewhere, this Agreement shall not
be affected.

      7.5 The construction, performance, and execution of this Agreement shall
be governed by the laws of the State of Arizona. Any disputes between the
parties to the Agreement shall be brought in the state or federal courts of
Arizona.

      7.6 DR. SCHLIEF warrants that he has good and marketable title to the
inventions claimed under PATENT RIGHTS. DR. SCHLIEF does not warrant the
validity of any patents or that practice under such patents shall be free of
infringement. EXCEPT AS EXPRESSLY SET FORTH IN THIS PARAGRAPH 7.6, IMARX,
AFFILIATED COMPANIES AND SUBLICENSEES AGREE THAT THE PATENT RIGHTS ARE PROVIDED
"AS IS", AND THAT DR. SCHLIEF MAKES NO REPRESENTATION OR WARRANTY WITH RESPECT
TO THE PERFORMANCE OF LICENSED PRODUCT(S) INCLUDING THEIR SAFETY, EFFECTIVENESS,
OR COMMERCIAL VIABILITY. DR. SCHLIEF DISCLAIMS ALL WARRANTIES WITH REGARD TO
PRODUCT(S) UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES,
EXPRESS OR IMPLIED, OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE.
NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, DR. SCHLIEF ADDITIONALLY
DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF DR. SCHLIEF, FOR
DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL, AND
CONSEQUENTIAL DAMAGES, ATTORNEYS' AND EXPERTS' FEES, AND COURT COSTS (EVEN IF
DR. SCHLIEF HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS),
ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR

<PAGE>

                                       10                       January 4, 2005

SALE OF THE PRODUCT(S) UNDER THIS AGREEMENT. IMARX, AFFILIATED COMPANIES AND
SUBLICENSEES ASSUME ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED
BY A LICENSED PRODUCT AS DEFINED IN THIS AGREEMENT MANUFACTURED, USED, OR SOLD
BY IMARX, ITS SUBLICENSEES AND AFFILIATED COMPANIES.

      7.7 DR. SCHLIEF will not, under the provisions of this Agreement or
otherwise, have control over the manner in which IMARX or its AFFILIATED
COMPANIES or its sublicensees or those operating for its account or third
parties who purchase LICENSED PRODUCT(S) from any of the foregoing entities,
practice the inventions of LICENSED PRODUCT(S). Practice of the inventions
covered by LICENSED PRODUCT(S), by an AFFILIATED COMPANY or an agent or a
sublicensee or a third party on behalf of or for the account of IMARX or by a
third party who purchases LICENSED PRODUCT(S) from the IMARX, shall be
considered the Company's practice of said inventions for purposes of this
Paragraph 7.7.

      7.8 Prior to initial human testing or first commercial sale of any
LICENSED PRODUCT in any particular country, IMARX shall establish and maintain,
in each country in which IMARX, an AFFILIATED COMPANY or sublicensee shall test
or sell LICENSED PRODUCT(S), product liability or other appropriate insurance
coverage appropriate to the risks involved in marketing LICENSED PRODUCT(S) and
will upon request present evidence to DR. SCHLIEF that such coverage is being
maintained.

      7.9 This Agreement constitutes the entire understanding between the
parties with respect to the obligations of the parties with respect to the
subject matter hereof, and supersedes and replaces all prior agreements,
understandings, writings, and discussions between the parties relating to said
subject matter.

      7.10 This Agreement may be amended and any of its terms or conditions may
be waived only by a written instrument executed by the authorized officials of
the parties or, in the case of a waiver, by the party waiving compliance. The
failure of either party at any time or times to require performance of any
provision hereof shall in no manner affect its right at a later time to enforce
the same. No waiver by either party of any condition or term in any one or more
instances shall be construed as a further or continuing waiver of such condition
or term or of any other condition or term.

      7.13 This Agreement shall be binding upon and inure to the benefit of and
be enforceable

<PAGE>

                                       11                        January 4, 2005

by the parties hereto and their respective successors and permitted assigns.

      7.14 Upon termination of this Agreement for any reason, Paragraphs 5.3,
6.4, 7.6, and 7.7 shall survive termination of this Agreement.

      IN WITNESS WHEREOF the respective parties hereto have executed this
Agreement by their duly authorized officers on the date appearing below their
signatures.

IMARX THERAPEUTICS, INC.                DR. SCHLIEF

By /s/ Evan Unger                       By /s/ Reinhard Schlief
   ---------------------------------       -------------------------
   Evan Unger, M.D., President & CEO       Dr. med. Reinhard Schlief

Date: 1-4-05                            Date 1-6-05

<PAGE>

                                    EXHIBIT A

                                     WARRANT

         THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE
HEREOF HAVE NOT BEEN REGISTERED UNDER THE FEDERAL SECURITIES ACT OF 1933, AS
AMENDED, OR THE SECURITIES LAWS OF ANY STATE. THIS WARRANT AND ANY OF SUCH
SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE
TRANSFERRED IN THE ABSENCE OF REGISTRATION UNDER SAID ACTS AND ALL OTHER
APPLICABLE SECURITIES LAWS UNLESS AN EXEMPTION FROM REGISTRATION IS AVAILABLE.

                          WARRANT TO PURCHASE SHARES OF
                    COMMON STOCK OF IMARX THERAPEUTICS, INC.

                        Date of Issuance: January 4, 2005

         THIS CERTIFIES that, for value received, Dr. med. Reinhard Schlief (the
"Holder") is entitled to purchase, subject to the provisions of this warrant,
from IMARX THERAPEUTICS, INC., a Delaware corporation (the "Company"), at the
Exercise Price described in Section 2.2, shares of the $0.0001 par value Common
Stock of the Company as adjusted in accordance with the provisions hereof. This
warrant is hereinafter referred to as the "Warrant," and the shares of Common
Stock issuable pursuant to the terms hereof are hereinafter sometimes referred
to as "Warrant Shares."

         This Warrant entitles the Holder to purchase, effective from the date
hereof until January 4, 2010 (the "Expiration Date"), Twenty Thousand (20,000)
shares of Common Stock. This Warrant shall be exercisable in whole or in part,
and at any time, or from time to time, on or before the Expiration Date.

                                    ARTICLE I
                               CERTAIN DEFINITIONS

         For all purposes of this Warrant, unless the context otherwise
requires, the following terms shall have the following respective meanings:

         "Act": the federal Securities Act of 1933, as amended, or any similar
federal statute, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time.

         "CASHLESS EXERCISE": an exercise of Warrants in which, in lieu of
payment of the Exercise Price, the Holder elects to receive a lesser number of
shares of Common Stock such that the value of the Common Stock that the Holder
would otherwise have been entitled to receive but has agreed not to receive, as
determined by the average of the closing prices of such shares over the thirty
(30) day period ending three (3) days prior to the date of exercise, is equal to
the Exercise Price with respect to such exercise. A Holder may only elect a
Cashless Exercise if the Common Stock issuable by the Company on such exercise
is publicly traded.

<PAGE>

         "COMMON STOCK": the Company's authorized Common Stock of $0.0001 par
value per share, as such class existed on the date of this Warrant.

         "COMMISSION": the United States Securities and Exchange Commission, or
any other federal agency then administering the Act.

         "COMPANY": IMARX THERAPEUTICS, INC., a Delaware corporation,
headquartered at 1635 East 18th St., Tucson, Arizona 85719, and any other
corporation assuming or required to assume the Warrants pursuant to Article VII.

         "EXERCISE PRICE": defined in Section 2.2.

         "PERSON": any individual, corporation, partnership, limited liability
company, trust, unincorporated organization and any government, and any
political subdivision, instrumentality or agency thereof.

         "WARRANT OFFICE": defined in Section 3.1.

         "WARRANT SHARES": the shares of Common Stock purchasable by the Holder
of this Warrant upon the exercise of this Warrant.

                                   ARTICLE II
                               EXERCISE OF WARRANT

         2.1 Exercise of Warrant. All or any part of the Warrant represented by
this Warrant Certificate may be exercised commencing on January 4, 2005 and
ending at 5 p.m. Eastern Time on January 4, 2010 by surrendering this Warrant
Certificate, together with appropriate instructions, duly executed by the Holder
or by its duly authorized attorney, at the office of the Company, or at such
other office or agency as the Company may designate. The date on which the
Company receives such instructions shall be the date of exercise. If the Holder
has elected a Cashless Exercise, such instructions shall so state. Upon receipt
of notice of exercise, the Company shall immediately instruct its transfer agent
to prepare certificates for the Common Stock to be received by the Holder upon
completion of the Warrant exercise. When such certificates are prepared, the
Company shall notify the Holder and deliver such certificates to the Holder or
as per the Holder's instructions immediately upon payment in full by the Holder,
in lawful money of the United States, of the Exercise Price payable with respect
to the Common Stock being purchased, if any.

         If fewer than all the Common Stock purchasable under the Warrant are
purchased, the Company will, upon such partial exercise, execute and deliver to
the Holder a new Warrant Certificate (dated the date hereof), in form and tenor
similar to this Warrant Certificate, evidencing that portion of the Warrant not
exercised. The Common Stock to be obtained on exercise of the Warrant will be
deemed to have been issued, and any person exercising the Warrants will be
deemed to have become a holder of record of those shares, as of the date of the
payment of the Exercise Price.

                                       2
<PAGE>

         2.2 Exercise Price. The exercise price for any Warrant Share shall be
equal to $3.00 per share of Common Stock; such price may be adjusted from time
to time pursuant to the terms of Article V.

         2.3 Shares to be Fully Paid and Nonassessable. All shares of Common
Stock issued upon the exercise of this Warrant shall be validly issued, fully
paid and nonassessable.

         2.4 No Fractional Shares to be Issued. The Company shall not be
required upon any exercise of this Warrant to issue a certificate representing
any fraction of a share of Common Stock.

         2.5 Legend on Warrant Shares. Each certificate for shares initially
issued upon exercise of this Warrant, unless at the time of exercise such shares
are registered under the Act, shall bear the following legends (and any
additional legend required by the Agreement, any national securities exchanges
upon which such shares may, at the time of such exercise, be listed or under
applicable securities laws):

                  The securities represented by this certificate have not been
         registered under the Securities Act of 1933, as amended (the "Act"), or
         the securities laws of any state. They may not be sold, transferred,
         assigned, pledged, hypothecated, encumbered, or otherwise disposed of
         in the absence of registration under said Act and all other applicable
         securities laws, unless an exemption from registration is available.

                  The securities represented by this certificate are subject to
         the Company's right of first refusal set forth in the issuer's bylaws,
         and none of such securities, or any interest therein, shall be
         transferred, pledged, encumbered or otherwise disposed of except as
         provided in such bylaws, a copy of which is on file in the Company's
         office and will be made available for inspection to any properly
         interested person without charge upon written request.

         Any certificate issued at any time in exchange or substitution for any
certificate bearing such legends (except a new certificate issued upon
completion of a public distribution pursuant to a registration statement under
the Act of the securities represented thereby) shall also bear the above legends
unless, in the opinion of counsel to the Company, the securities represented
thereby need no longer be subject to the restrictions on transferability. The
provisions of Article IV shall be binding upon all subsequent Holders of this
Warrant.

         2.6 Acknowledgment of Continuing Obligation. The Company will, at the
time of any exercise of this Warrant in whole or in part, upon request of the
Holder hereof, acknowledge in writing its continuing obligation to such Holder
in respect of any rights to which the Holder shall continue to be entitled after
exercise in accordance with this Warrant; provided, however, that the failure of
the Holder to make any such request shall not affect the continuing obligation
of the Company to the Holder in respect of such rights.

                                       3
<PAGE>

                                   ARTICLE III
                       WARRANT OFFICE; TRANSFER, DIVISION
                           OR COMBINATION OF WARRANTS

         3.1 Warrant Office. The Company shall maintain an office for certain
purposes specified herein (the "Warrant Office"), which office shall initially
be the Company's location set forth in Article I hereof, and may subsequently be
such other office of the Company or of any transfer agent of the Common Stock in
the continental United States as to which written notice has previously been
given to all of the Holders of the Warrants.

         3.2 Ownership of Warrant. The Company may deem and treat the Person in
whose name this Warrant is registered as the Holder and owner hereof
(notwithstanding any notations of ownership or writing hereon made by anyone
other than the Company) for all purposes and shall not be affected by any notice
to the contrary, until presentation of this Warrant for registration of transfer
as provided in this Article III.

         3.3 Transfer of Warrant. The Company agrees to maintain at the Warrant
Office books for the registration of this Warrant. Subject to the provisions of
Article IV, this Warrant and the rights hereunder are not transferable, in whole
or in part, by the Holder.

         3.4 Division or Combination of Warrants. Subject to Article IV hereof,
this Warrant maybe divided or combined with any other Warrant or warrants held
by Holder.

         3.5 Expenses of Delivery of Warrants. The Company shall pay all
expenses, taxes (other than transfer taxes and any federal or state income
taxes), and other charges payable in connection with the preparation, issuance
and delivery of new Warrants hereunder.

                                   ARTICLE IV
                             RESTRICTION ON TRANSFER

         4.1 Restrictions on Transfer. This Warrant and the rights hereunder are
not transferable, in whole or in part, by the Holder. Notwithstanding any
provisions contained in this Warrant to the contrary, this Warrant shall not be
exercisable except upon the conditions specified in this Article IV, which
conditions are intended, among other things, to insure compliance with the
provisions of the Act in respect of the exercise of the Warrant. The Holder of
this Warrant, by acceptance hereof, agrees that it will not exercise this
Warrant prior to delivery to the Company of any required opinion of the Holder's
counsel (as the opinion and counsel are described in Section 4.2 hereof). The
Warrant Shares are subject to the Company's right of first refusal set forth in
the Company's bylaws.

         4.2 Opinion of Counsel. If in the opinion of counsel reasonably
acceptable to the Company, a proposed exercise of this Warrant may be effected
without registration of this Warrant under the Act, the Holder of this Warrant
shall be entitled to exercise this Warrant in accordance with the proposed
method of disposition; provided, however, that if the method of disposition
would, in the opinion of such counsel, require that the Company take any action
or execute and file with the Commission or deliver to the Holder or any other
person any notice, form or document in order to establish the entitlement of the
Holder to take advantage of such

                                       4
<PAGE>

method of disposition, the Company agrees, at the cost of the Holder, to
promptly take any necessary action or execute and file or deliver any necessary
form or document.

                                    ARTICLE V
                 ADJUSTMENT OF WARRANT SHARES AND EXERCISE PRICE

         5.1 Anti-Dilution Adjustments. If at any time after this Warrant
becomes exercisable, the Company (i) pays a stock dividend of Common Stock to
holders of Common Stock, (ii) institutes a stock split or a reverse stock split
of its Common Stock, or (iii) reclassifies its capital structure in any other
way, then in each such case, the number of shares of Common Stock into which
this Warrant is exercisable shall be adjusted as if the Warrant Shares were
outstanding immediately prior to the time of such event, and the Exercise Price
shall be adjusted accordingly.

         5.2 Notice to Holder. Whenever the Company proposes to take any action
that would cause an anti-dilution adjustment, the Company will provide the
Holder hereof with written notice of such change and the number of Warrant
Shares into which this Warrant would then be exercisable and the applicable
Exercise Price. Such notice will be provided no less than ten (10) days prior to
the effective date of any such action.

                                   ARTICLE VI
                      ADDITIONAL NOTICES TO WARRANT HOLDER

[INTENTIONALLY LEFT BLANK]

                                   ARTICLE VII
                   RECLASSIFICATION, REORGANIZATION OR MERGER

         In case of any reclassification, capital reorganization or other change
of outstanding shares of Common Stock of the Company, or in case of any
consolidation or merger of the Company with or into another corporation (other
than a merger with a subsidiary in which merger the Company is the continuing
corporation or that does not result in any reclassification, capital
reorganization or other change of outstanding shares of Common Stock), the
Company shall cause effective provision to be made so that the Holder hereof
shall have the right thereafter by exercising this Warrant to purchase the kind
and amount of shares of stock and other securities, cash and/or property
receivable upon such reclassification, capital reorganization or other change,
consolidation or merger, by a Holder of the number of shares of Common Stock
that might have been purchased upon exercise of this Warrant immediately prior
to such reclassification, change, consolidation or merger. Any such provision
shall include provision for adjustments that shall be as nearly equivalent as
may be practicable to the adjustments herein provided of the Exercise Price and
the number of Warrant Shares purchasable and receivable upon the exercise of
this Warrant. The foregoing provisions of this Article VII shall similarly apply
to successive reclassifications, capital reorganizations and changes of shares
of Common Stock and to successive consolidations and mergers.

                                       5
<PAGE>

                                  ARTICLE VIII
                        CERTAIN COVENANTS OF THE COMPANY

         8.1 Reservation of Common Stock. The Company covenants and agrees that
it will reserve and set apart and have at all times, free from preemptive
rights, a number of shares of authorized but unissued Common Stock or other
securities or property deliverable upon the exercise of this Warrant sufficient
to enable it at any time to fulfill all its obligations hereunder.

         8.2 Piggyback Registration. Holder shall have unlimited piggyback
registration rights for any shares purchased hereunder on a pari passu basis
with the Investors party to that certain Amended and Restated Investor Rights
Agreement dated October 10, 2002 among the Company and the parties thereto, as
amended from time to time (the "Investor Rights Agreement"). Holder hereby
agrees that such Holder shall not sell, transfer, make any short sale of, grant
any option for the purchase of, or enter into any hedging or similar transaction
with the same economic effect as a sale, any Common Stock (or other securities)
of the Company held by such Holder (other than those included in the
registration) for a period specified by the representative of the underwriters
of Common Stock (or other securities) of the Company not to exceed one hundred
eighty (180) days following the effective date of a registration statement of
the Company filed under the Securities Act; provided that all officers and
directors of the Company and holders of at least five percent (5%) of the
Company's voting securities (other than Arizona Angels Fund I, LLC) enter into
similar agreements. Each Holder agrees to execute and deliver such other
agreements as may be reasonably requested by the Company or the underwriter
which are consistent with the foregoing or which are necessary to give further
effect thereto. The Company may impose stop-transfer instructions with respect
to the shares of Common Stock (or other securities) subject to the foregoing
restriction until the end of said one hundred eighty (180) day period.

                                   ARTICLE IX
                                  MISCELLANEOUS

         9.1 Waiver and Amendment. Any term or provision of this Warrant may be
waived at any time by the party who or that is entitled to the benefits thereof,
and any term or provision of this Warrant may be amended or supplemented at any
time by agreement of the Holder hereof and the Company, except that any waiver
of any term or condition, or any amendment or supplementation, of this Warrant
must be in writing. A waiver of any breach or failure to enforce any of the
terms or conditions of this Warrant shall not in any way affect, limit or waive
a party's rights hereunder at any time to enforce strict compliance thereafter
with any term or condition of this Warrant.

         9.2 Filing of Warrant. A copy of this Warrant shall be filed in the
records of the Company.

         9.3 Notice. Any notice or other document required or permitted to be
given or delivered to the Holder shall be delivered personally, or sent by
certified or registered mail, to Holder at the last address shown on the books
of the Company maintained at the Warrant Office for the registration of the
Warrant or at any more recent address of which the Holder shall have notified
the Company in writing. Any notice or other document required or permitted to be

                                       6
<PAGE>

given or delivered to the Company shall be delivered at, or sent by certified or
registered mail to, the Warrant Office, or such other address within the United
States of America as shall have been furnished by the Company to the Holder.

         9.4 Limitation of Liability; Not Shareholders. No provision of this
Warrant shall be construed as conferring upon the Holder the right to vote or
consent at meetings of shareholders, receive dividends or receive notice other
than as herein expressly provided. No provision hereof, in the absence of
affirmative action by the Holder hereof to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of Holder for the exercise price of any Warrant Shares or as a
shareholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.

         9.5 Loss, Destruction, Etc. of Warrant. Upon receipt of evidence
satisfactory to the Company of the loss, theft, mutilation or destruction of the
Warrant, and in the case of any such loss, theft or destruction, upon delivery
of a bond of indemnity in such form and amount as shall be reasonably
satisfactory to the Company, or in the event of such mutilation, upon surrender
and cancellation of the Warrant, the Company will make and deliver a new
Warrant, of like tenor, in lieu of such lost, stolen, destroyed or mutilated
Warrant. Any Warrant issued under the provisions of this Section 9.5 in lieu of
any Warrant alleged to be lost, destroyed or stolen, or in lieu of any mutilated
Warrant, shall constitute an original contractual obligation on the part of the
Company.

         9.6 Governing Law. This Warrant shall be governed by and construed in
accordance with the internal laws of the State of Delaware, without giving
effect to any law or rule that would cause the laws of any jurisdiction other
than the State of Delaware to be applied.

         IN WITNESS WHEREOF, the Company has caused this Warrant to be signed in
its name by its President and its corporate seal to be impressed hereon and
attested by its Secretary.

                                      THE COMPANY:

                                      IMARX THERAPEUTICS, INC.

                                      By:
                                         --------------------------------------
                                      Name:
                                           ------------------------------------
                                      Title:  President

Attest:

----------------------------------
                       , Secretary
-----------------------

                                       7<PAGE>
                                                                    EXHIBIT 10.7

                         EXCLUSIVE SUBLICENSE AGREEMENT
                        Re: UNMC Docket Nos. 63095 series

This Agreement having the effective date of October 10, 2003 ("EFFECTIVE DATE")
is made between UNEMED Corporation, 986099 Nebraska Medical Center, Omaha,
Nebraska 68198-6099 ("UNEMED") and ImaRx Therapeutics, Incorporated, 1635 East
18th Street, Tucson, AZ 85719 ("LICENSEE").

WHEREAS, the University of Nebraska Medical Center ("UNMC") desires to license
and otherwise commercialize certain technology resulting from the research of
its faculty; and

WHEREAS, UNEMED is a biomedical technology development company charged with and
having authority to assist UNMC in the licensing and commercial development of
its technology; and

WHEREAS, ImaRx Therapeutics, Incorporated is desirous of licensing certain UNMC
technology with the intent of furthering its commercial development;

In consideration of the mutual promises and covenants set forth below, the
parties hereto agree as follows:

                                    ARTICLE I

                                   DEFINITIONS

As used in this Agreement, the following terms shall have the following
meanings:

1.1 AFFILIATE: any company, corporation, or business in which LICENSEE owns or
controls at least fifty percent (50%) of the voting stock or other ownership.
Unless otherwise specified, the term LICENSEE includes AFFILIATES.

1.2 FIELD: Therapeutic applications of Non-PESDA (Non-perfluorocarbon enhanced
sonicated dextrose albumin) microbubbles for the treatment of thrombosis, as
described in UNMC Docket Series 63095.

1.3 UNEMED: UNEMED Corporation, a for-profit Nebraska corporation having offices
at 701 S. 42nd Street, 986099 Nebraska Medical Center, Omaha, Nebraska,
69198-6099.

1.4 LICENSED PROCESSES: the processes covered by issued claims of PATENT RIGHTS,
on a country-by-country basis, that if made used, sold, imported or offered for
sale would constitute, but for the license granted to Company pursuant to this
Agreement, an infringement of a claim of PATENT RIGHTS (infringement shall
include, but is not limited to, direct, contributory, or inducement to
infringe).

<PAGE>

1.5 LICENSED PRODUCTS: products covered by issued claims of PATENT RIGHTS , on a
country-by-country basis, that if made, used, sold, imported or offered for sale
would constitute, but for the license granted to Company pursuant to this
Agreement, an infringement of a claim of PATENT RIGHTS (infringement shall
include, but is not limited to, direct, contributory, or inducement to
infringe).

1.6 LICENSEE: ImaRx Therapeutics, 1635 East 18th Street, Tucson, AZ 85719

1.7 NET SALES: the amount billed, invoiced, or received (whichever occurs first)
for sales, leases, or other transfers of LICENSED PRODUCTS, less:

     (a) customary trade, quantity or cash discounts and non-affiliated brokers'
or agents' commissions actually allowed and taken;

     (b) amounts repaid or credited by reason of rejection or return;

     (c) to the extent separately stated on purchase orders, invoices, or other
documents of sale, taxes levied on and/or other governmental charges made as to
production, sale, transportation, delivery or use and paid by or on behalf of
LICENSEE or sublicensees; and

     (d) reasonable charges for delivery or transportation or insurance provided
by third parties, if separately stated.

     NET SALES also includes the fair market value of any non-cash consideration
received by LICENSEE or sublicensees (other than research and development
payments as set forth in 4.2(a)) for the sale, lease, or transfer of LICENSED
PRODUCTS.

1.8 NON-COMMERCIAL RESEARCH PURPOSES: use of PATENT RIGHTS for non-commercial
academic research or other non-commercial scholarly purposes which are
undertaken at a non-profit or governmental institution; provided however that
such entity does not use the PATENT RIGHTS in the production or manufacture of
products for sale or the performance of services for a fee.

1.9 NON-ROYALTY SUBLICENSE INCOME: Sublicense issue fees, sublicense maintenance
fees, sublicense milestone payments, and similar non-royalty payments made by
sublicensees to LICENSEE on account of sublicenses pursuant to this Agreement.

1.10 PATENT RIGHTS:

Patent applications associated with Tech ID # 95009 (the entire 63095 Family)
Title: New Agent for the Treatment of Thrombosis

                                                        Patent #
UNMC Docket #                                      Title (issue date)
-------------                                      ------------------
63095                  5,648,098       Thrombolytic Agents and Methods of
                                       Treatment for Thrombosis (issued 7/15/97)

63095.1                5,980,950       Thrombolytic Agents and Methods of

<PAGE>

           divisional of 63095)       Treatment for Thrombosis (issued 11/09/99)

63095.2           6,197,345           Thrombolytic Agents and Methods of
           (continuation of 63095.1)  Treatment for Thrombosis (issued 3/06/01)

63095.3           Filed               Thrombolytic Agents and Methods of
           (continuation of 63095.2)  Treatment for Thrombosis (pending)

the inventions disclosed and claimed therein, divisional patent applications,
issued patents, CIP applications to the extent any new matter reads on claims of
a parent application, reissued and reexamined patents, all limited by FIELD to
be included within this agreement, and to the extent they are owned or
controlled by INSTITUTIONS, any and all foreign patents and patent applications
corresponding thereto.

1.11 TERRITORY: Worldwide

1.12 The terms "Public Law 96-517" and "Public Law 98-620" include all
amendments to those statutes.

1.13 The terms "sold" and "sell" include, without limitation, leases and other
transfers and similar transactions.

1.14 INSTITUTIONS: The Board of Regents of the University of Nebraska, a public
body corporate, doing business as the University of Nebraska Medical Center,
986099 Nebraska Medical Center, Omaha, Nebraska, USA, 68198-6099.

                                   ARTICLE II

                                 REPRESENTATIONS

2.1 INSTITUTIONS are owners by assignment from inventor(s) of their entire
right, title and interest in PATENT RIGHTS, in the foreign patent applications
corresponding thereto, and in the inventions claimed therein.

2.2 UNEMED has the authority from INSTITUTIONS to issue licenses under PATENT
RIGHTS. If for any reason UNEMED and INSTITUTIONS terminate their agreement
providing such authority, or UNEMED ceases to exist, this Agreement shall
automatically be reassigned to INSTITUTIONS.

2.3 UNEMED is committed to the policy that ideas or creative works produced at
INSTITUTIONS should be used for the greatest possible public benefit, and
believes that every reasonable incentive should be provided for the prompt
introduction of such ideas into public

<PAGE>

use, all in a manner consistent with the public interest.

2.4 LICENSEE is prepared and intends to use commercially reasonable efforts
develop the invention and to bring to market products, which are subject to this
Agreement.

2.5 LICENSEE is desirous of obtaining an exclusive license in the TERRITORY in
order to practice the above-referenced invention covered by PATENT RIGHTS in the
United States and in certain foreign countries, and to manufacture or have
manufactured, use, import, sell and have sold in the commercial market the
products made in accordance therewith, and UNEMED is desirous of granting such a
license to LICENSEE in accordance with the terms of this Agreement.

<PAGE>

                                   ARTICLE III

                                 GRANT OF RIGHTS

3.1 UNEMED hereby grants to LICENSEE and LICENSEE accepts, subject to the terms
and conditions hereof, in the TERRITORY and in the FIELD:

     an exclusive commercial license under PATENT RIGHTS,

     to research and develop, make and have made, to use and have used, to sell
and have sold, offer for sale and import the LICENSED PRODUCTS, and to practice
the LICENSED PROCESSES, for the life of the PATENT RIGHTS. Such licenses shall
include the right to grant sublicenses. In order to provide LICENSEE with
commercial exclusivity for so long as the license under PATENT RIGHTS remains
exclusive, UNEMED agrees that it will not grant licenses under PATENT RIGHTS to
others except as required by INSTITUTIONS' obligations in paragraph 3.2(a) or as
permitted in paragraph 3.2(b) .

3.2 The granting and exercise of this license is subject to the following
conditions:

     (a) U.S. Public Law 96-517, U.S. Public Law 98-620; if a subject invention;
the Memorandum of Agreement between the INSTITUTIONS and UNEMED dated March 31,
1998; the Technology Development Program Agreement dated November 27, 1991 .

     (b) UNEMED on behalf of INSTITUTIONS reserves the right to

          (i) make, have made, provide and use for UNEMED's and INSTITUTION'S
          NON COMMERCIAL RESEARCH PURPOSES the subject matter described and
          claimed in PATENT RIGHTS, including the ability to distribute any
          UNEMED- or INSTITUTION-owned materials within the PATENT RIGHTS for
          NON-COMMERCIAL RESEARCH PURPOSES as is customary in the academic
          community.

          (ii) grant to others licenses to use and develop the PATENT RIGHTS
          outside of the FIELD of this agreement.

     (c) LICENSEE shall use commercially reasonable efforts to effect
introduction of the LICENSED PRODUCTS or LICENSED PROCESS into the commercial
market as soon as

<PAGE>

practicable, consistent with sound and reasonable business practice and
judgment; thereafter, until the expiration of this Agreement, LICENSEE shall
endeavor to keep LICENSED PRODUCTS or LICENSED PROCESSES reasonably available to
the public. Licensee shall use commercially reasonable efforts to meet the
milestones outlined in Section 3.2 (c), (i)-(iii) described below:

          (i) within three (3) years from the EFFECTIVE DATE of this Agreement,
          LICENSEE shall file an IND with the US FDA for a LICENSED PRODUCT or
          LICENSED PROCESS.

          (ii) within four (4) years from the EFFECTIVE DATE of this agreement,
          LICENSEE shall commence studies in humans with a LICENSED PRODUCT or
          LICENSED PROCESS.

          (iii) within six (6) years from the EFFECTIVE DATE of this agreement,
          LICENSEE shall commence Phase II studies with a LICENSED PRODUCT or
          LICENSED PROCESS.

     (d) At any time after 3 years from the effective date of this Agreement,
UNEMED may terminate or render this license non-exclusive if, in UNEMED's
reasonable judgment, the Progress Reports furnished by LICENSEE do not
demonstrate that LICENSEE has satisfied one of the following:

          (i) has succeeded in meeting the milestones as presented in
          3.2(c)i-iii, or

          (ii) is engaged in research, development, manufacturing, marketing or
          sublicensing activity (which includes making sublicenses reasonably
          available) appropriate to achieving 3.2(d)i, or

          (iii) has put the licensed subject matter into commercial use in at
          least one country in the TERRITORY hereby licensed, directly or
          through a sublicense, and is keeping the license subject matter
          reasonably available to the public.

     (e) In all sublicenses granted by LICENSEE hereunder, LICENSEE shall
include a requirement that the sublicensee use its commercially reasonable
efforts to bring the subject matter of the sublicense into commercial use as
quickly as is reasonably possible. LICENSEE

<PAGE>

shall further provide in such sublicenses that such sublicenses are subject and
subordinate to the terms and conditions of this Agreement applicable to a
sublicense, except: (i) the sublicensee may not further sublicense; and (ii) the
rate of royalty on NET SALES paid by the sublicensee to the LICENSEE. Copies of
all sublicense agreements shall be provided promptly to UNEMED. LICENSEE may
redact confidential information from such sublicenses.

     (f) After clinical or other evidence, provided in writing by UNEMED, to
LICENSEE, reasonably demonstrates the practicality of a particular use of PATENT
RIGHTS, which is not being developed or commercialized by LICENSEE, LICENSEE
shall either provide UNEMED with a reasonable development plan and start
development or attempt to reasonably sublicense of the particular PATENT RIGHTS
to a third party. If within six (6) months of such notification by UNEMED,
LICENSEE has not initiated such development efforts or sublicensed that
particular use of PATENT RIGHTS, UNEMED may reduce the FIELD to the extent of
such particular use of PATENT RIGHTS, as described in such notice, of this
license for such particular use of PATENT RIGHTS. This Paragraph 3.2 (f) shall
not be applicable if LICENSEE reasonably demonstrates to UNEMED that
commercializing such LICENSED PRODUCT(S) or granting such a sublicense would
have a potentially adverse commercial effect upon marketing or sales of the
LICENSED PRODUCTS developed and being sold by LICENSEE.

     (g) A license in any other field of use in addition to the FIELD shall be
the subject of a separate agreement and shall require LICENSEE's submission of
evidence, satisfactory to UNEMED, demonstrating LICENSEE's willingness and
ability to develop and commercialize in such other field of use the kinds of
products or processes likely to be encompassed in such other field.

     (h) During the period of exclusivity of this license in the United States,
LICENSEE shall cause any LICENSED PRODUCT, if a subject invention, produced for
sale in the United States to be manufactured substantially in the United States.

3.3 All rights reserved to the United States Government and others under Public
Law 96-517, and Public Law 98-620, if a subject invention, shall remain and
shall in no way be affected by this Agreement.

<PAGE>

                                   ARTICLE IV

                                    ROYALTIES

4.1 LICENSEE shall pay to UNEMED a non-refundable license royalty fee in the sum
of ten thousand dollars ($10,000.00) upon execution of this Agreement.

4.2 (a) LICENSEE shall pay to UNEMED during the term of this Agreement a royalty
of two percent (2% ) of NET SALES by LICENSEE and sublicensees. Should LICENSEE
be required to pay running royalties to a third party on any patent rights not
licensed hereunder ("Other Royalties") in order to make, use, import or sell a
particular LICENSED PRODUCT or LICENSED PROCESS, LICENSEE shall be entitled to
credit half (50%) of such Other Royalties against the running royalty due,
provided that the running royalties shall not be reduced below fifty percent
(50%) of those that would otherwise be due UNEMED for that LICENSED PRODUCT or
LICENSED PROCESS. In the case of sublicenses, LICENSEE shall also pay to UNEMED
a royalty of fifty percent (50%) of NON-ROYALTY SUBLICENSE INCOME, provided that
the sublicense grant is solely for PATENT RIGHTS and grants no additional rights
(including but not limited to patent, tangible property, know-how, data,
trademarks) to the sublicense which are owned or controlled by LICENSEE. Such
consideration shall include any upfront, annual, milestone or other payments and
value above fair market value of any equity purchased by sublicensee.
Consideration shall not include any research or development money paid to
LICENSEE to conduct research in the FIELD pursuant to a research plan and
budget.

Only one royalty shall be due under this Agreement for any given LICENSED
PRODUCT or LICENSED PROCESS if covered by multiple patents under PATENT RIGHTS.

Payment of royalty for any given LICENSED PRODUCT or LICENSED PROCESS does not
require either determination of infringement or validity of PATENT RIGHTS prior
to being paid to UNEMED, but rather on presumption of validity. Any royalties
already paid to UNEMED are nonrefundable should a court of competent
jurisdiction render a determination of invalidity of PATENT RIGHTS.

     (b) If the license pursuant to this Agreement is converted to a
non-exclusive one and if other non-exclusive licenses in the same FIELD and
TERRITORY are granted, the above royalties shall not exceed the royalty rate to
be paid by other licensees in the same FIELD and TERRITORY during the term of
the non-exclusive license.

     (c) On sales between LICENSEE and its AFFILIATES or sublicensees for
resale, the royalty shall be paid on the NET SALES of the AFFILIATE or
sublicensee.

4.3 No later than January 1 of the third calendar year after the effective date
of this Agreement,

<PAGE>

as provided below, LICENSEE shall pay to UNEMED the following non-refundable
license maintenance royalty and/or advance on royalties. Such payments may be
credited against running royalties due for that calendar year and Royalty
Reports shall reflect such a credit. Such payments shall not be credited against
milestone payments (if any) or against royalties due for any subsequent calendar
year.

January 1, 2006,        $3,000
January 1, 2007 ,       $3,000
January 1, 2008,        $4,000
each year thereafter,   $7,000

                                    ARTICLE V

                                    REPORTING

5.1 Prior to signing this Agreement, LICENSEE has provided to UNEMED a written
research and development plan under which LICENSEE intends to bring the subject
matter of the licenses granted hereunder into commercial use upon execution of
this Agreement. Such plan includes projections of sales, proposed marketing
efforts and the plan for achieving milestones outlined in Article III, Section
3.2 (c) (i) - (iii). A copy of this plan is included in Appendix A of this
agreement.

5.2 No later than sixty (60) days after June 30 of each calendar year, LICENSEE
shall provide to UNEMED a written annual progress report describing progress on
research and development, regulatory approvals, manufacturing, sublicensing,
marketing and sales during the most recent twelve (12) month period ending June
30 and plans for the forthcoming year. If multiple technologies are covered by
the license granted hereunder, the progress report shall provide the information
set forth above for each technology. If progress differs from that anticipated
in the plan required under Paragraph 5.1, LICENSEE shall explain the reasons for
the difference and propose a modified research and development plan for UNEMED's
review and approval. LICENSEE shall also provide any reasonable additional
information UNEMED reasonably request to evaluate LICENSEE's performance.

5.3 LICENSEE shall report to UNEMED the date of first sale of LICENSED PRODUCTS
(or results of LICENSED PROCESSES) in each country within sixty (60) days of
occurrence.

5.4 (a) Upon commencing sales of LICENSED PRODUCTS or LICENSED PROCESSES as
described in 5.3, LICENSEE shall thereafter submit to UNEMED within sixty (60)
days after each calendar half year ending June 30 and December 31, a Royalty
Report setting forth for such half year at least the following information:

<PAGE>

          (i) the number of LICENSED PRODUCTS sold by LICENSEE, its AFFILIATES
          and sublicensees in each country;

          (ii) total billings for such LICENSED PRODUCTS;

          (iii) an accounting for all LICENSED PROCESSES used or sold;

          (iv) deductions applicable to determine the NET SALES thereof;

          (v) the amount of NON-ROYALTY SUBLICENSE INCOME received by LICENSEE;
          and

          (vi) the amount of royalty due thereon, or, if no royalties are due to
          UNEMED for any reporting period, the statement that no royalties are
          due.

          Such report shall be certified as correct by an officer of LICENSEE
and shall include a detailed listing of all deductions from royalties.

     (b) LICENSEE shall pay to UNEMED with each such Royalty Report the amount
of royalty due with respect to such half year. LICENSEE shall specify, by Patent
number, which PATENT RIGHTS are utilized for each LICENSED PRODUCT and LICENSED
PROCESS included in the Royalty Report.

     (c) All payments due hereunder shall be deemed received when funds are
credited to UNEMED's bank account and shall be payable by check or wire transfer
in United States dollars. Conversion of foreign currency to U.S. dollars shall
be made at the conversion rate existing in the United States (as reported in the
New York Times or the Wall Street Journal) on the last working day of each
royalty period. No transfer, exchange, collection or other charges shall be
deducted from such payments.

     (d) All such reports and sublicenses provided to UNEMED by LICENSEE shall
be maintained in confidence by UNEMED except as required by law; however, UNEMED
may include in its usual reports annual amounts of royalties paid.

     (e) Late payments shall be subject to a charge of one and one half percent
(1 1/2%) per month.

5.5 In the event of acquisition, merger, change of corporate name, or change of
make- up, organization, or identity, LICENSEE shall notify UNEMED in writing
within thirty (30) days of such event.

5.6 If LICENSEE or any AFFILIATE or sublicensee (or optionee) does not qualify
as a "small

<PAGE>

entity" as provided by the United States Patent and Trademark Office, LICENSEE
must notify UNEMED immediately.

                                   ARTICLE VI

                                 RECORD KEEPING

6.1 LICENSEE shall keep, and shall require its AFFILIATES and sublicensees to
keep, accurate records (together with supporting documentation) of LICENSED
PRODUCTS made, used or sold under this Agreement, appropriate to determine the
amount of royalties due to UNEMED hereunder. Such records shall be retained for
at least three (3) years following the end of the reporting period to which they
relate. They shall be available during normal business hours for examination by
an accountant of nationally recognized stature selected by UNEMED and reasonably
acceptable to LICENSEE, for the sole purpose of verifying reports and payments
hereunder. UNEMED shall provide Company five (5) business days notice in writing
prior to examination. In conducting examinations pursuant to this paragraph,
UNEMED's accountant shall have access to all records, which UNEMED reasonably
believes to be relevant to the calculation of royalties under Article IV.

6.2 UNEMED's accountant shall not disclose to UNEMED any information other than
information relating to the accuracy of reports and payments made hereunder.

6.3 Such examination by UNEMED's accountant shall be at UNEMED's expense, except
that if such examination shows an underreporting or underpayment in excess of
five percent (5%) for any twelve (12) month period, then LICENSEE shall pay the
cost of such examination as well as any additional sum that would have been
payable to UNEMED had the LICENSEE reported correctly, plus interest on said sum
at the rate of one and one half per cent (1 1/2%) per month.

<PAGE>

                                   ARTICLE VII

               DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE

7.1 Upon execution of this Agreement, LICENSEE shall assume responsibility for
and reimburse UNEMED for all reasonable expenses UNEMED incurs related to the
maintenance of issued patent # 6,197,345. LICENSEE shall reimburse UNEMED within
sixty (60) days of receiving an invoice for all such expenses upon receipt of
invoices from UNEMED. Late payment of these invoices shall be subject to
interest charges of one and one-half percent (1 1/2%) per month. In the event
UNEMED grants rights to issued patent # 6,197,345 for development in a different
FIELD, responsibility for maintenance fees will thereafter be assumed by
subsequent licensee. UNEMED shall, in its sole discretion, be responsible for
the preparation, filing, prosecution and maintenance of any and all patent
applications and patents included in PATENT RIGHTS. UNEMED shall consult with
LICENSEE as to the preparation, filing, prosecution and maintenance of such
patent applications and patents which are within the FIELD and shall furnish to
LICENSEE copies of documents relevant to any such preparation, filing,
prosecution or maintenance.

7.2 UNEMED and LICENSEE shall cooperate fully in the preparation, filing,
prosecution and maintenance of PATENT RIGHTS and of all patents and patent
applications licensed in the FIELD to LICENSEE hereunder, executing all papers
and instruments or requiring members of UNEMED to execute such papers and
instruments so as to enable UNEMED to apply for, to prosecute and to maintain
patent applications and patents in UNEMED's name in any country. Each party
shall provide to the other prompt notice as to all matters which come to its
attention and which may affect the preparation, filing, prosecution or
maintenance of any such patent applications or patents. In particular, LICENSEE
must immediately notify UNEMED if LICENSEE or any AFFILIATE or sublicensee (or
optionee) does not qualify as a "small entity" as provided by the United States
Patent and Trademark Office.

7.3 LICENSEE may elect to surrender its PATENT RIGHTS in any country upon sixty
(60) days written notice to UNEMED. Such notice shall not relieve LICENSEE from
responsibility to reimburse UNEMED for patent-related expenses owed by LICENSEE
pursuant to paragraph 7.1 incurred prior to the expiration of the (60)-day
notice period (or such longer period specified in LICENSEE's notice).

                                  ARTICLE VIII

                                  INFRINGEMENT

8.1 With respect to any PATENT RIGHTS that are exclusively licensed to LICENSEE
pursuant to this Agreement, LICENSEE shall have the right to prosecute in its
own name and at its own expense any infringement of such patent, so long as such
license is exclusive at the time of the commencement of such action. UNEMED
agrees to notify LICENSEE promptly of each

<PAGE>

infringement of such patents of which UNEMED is or becomes aware. Before
LICENSEE commences an action with respect to any infringement of such patents,
LICENSEE shall give careful consideration to the views of UNEMED and to
potential effects on the public interest in making its decision whether or not
to sue.

8.2 (a) If LICENSEE elects to commence an action as described above, UNEMED
and/or INSTITUTIONS may, to the extent permitted by law, elect or be required to
join as a party in that action. Regardless of whether UNEMED and/or INSTITUTIONS
elect to join as a party, UNEMED and/or INSTITUTIONS shall cooperate fully with
LICENSEE in connection with any such action.

     (b) If UNEMED and/or INSTITUTIONS elect to join as a party pursuant to
subparagraph (a), joining parties shall jointly control the action with
LICENSEE.

     (c) LICENSEE shall reimburse UNEMED and/or INSTITUTIONS for any
pre-approved, reasonable costs incurred by LICENSEE's attorney on behalf of
UNEMED and/or INSTITUTIONS, including reasonable attorneys' fees incurred, as
part of an action brought by LICENSEE, irrespective of whether UNEMED and/or
INSTITUTIONS become a co-plaintiff.

     (d) UNEMED and/or INSTITUTIONS may, at their own expense, engage separate
counsel for such infringement action.

8.3 If LICENSEE elects to commence an action as described above, LICENSEE may
deduct from its royalty payments to UNEMED with respect to the patent(s) subject
to suit an amount not exceeding fifty percent (50%) of LICENSEE's expenses and
costs of such action, including reasonable attorneys' fees; provided, which
shall be prorated to reflect expenses relating to licensed PATENT RIGHTS among
all patents involved in litigation. However, such reduction shall not exceed
seventy five percent (75%) of the total royalty due to UNEMED with respect to
the patent(s) subject to suit for each calendar year. If such fifty percent
(50%) of LICENSEE's expenses and costs exceeds the amount of royalties deducted
by LICENSEE for any calendar year, LICENSEE may to that extent reduce the
royalties due to UNEMED from LICENSEE in succeeding calendar years, but never by
more than seventy five percent (75%) of the total royalty due in any one year
with respect to the patent(s) subject to suit.

8.4 No settlement, consent judgment or other voluntary final disposition of the
suit may be entered into without the prior written consent of UNEMED, which
consent shall not be unreasonably withheld.

8.5 Recoveries or reimbursements from actions commenced pursuant to this Article
shall first be applied to reimburse LICENSEE and UNEMED and/or INSTITUTIONS for
litigation costs not paid from royalties and then to reimburse UNEMED for
royalties deducted by LICENSEE

<PAGE>

pursuant to paragraph 8.3. Any remaining recoveries or reimbursements shall be
shared with LICENSEE, receiving sixty percent (60%) and UNEMED receiving forty
percent (40%). Should additional patents other than PATENT RIGHTS be involved in
the infringement suit, any recoveries and reimbursements shall be prorated and
allocated equally among the patents involved in the litigation, with UNEMED
sharing in reimbursements based upon the prorated share of the PATENT RIGHTS.

8.6 If LICENSEE elects not to exercise its right to prosecute an infringement of
the PATENT RIGHTS pursuant to this Article, UNEMED and/or INSTITUTIONS may do so
at their own expense, controlling such action and retaining all recoveries there
from. LICENSEE shall cooperate fully with UNEMED and/or INSTITUTIONS in
connection with any such action, however, UNEMED and/or INSTITUTIONS shall pay
any reasonable costs incurred by LICENSEE. UNEMED shall consult with LICENSEE
and consider any reasonable reasons as to why LICENSEE elects not to pursue an
infringement suit.

8.7 Without limiting the generality of paragraph 8.6, UNEMED may, at its
election and by notice to LICENSEE, establish a time limit of three (3) months
for LICENSEE to decide whether to prosecute any infringement of which UNEMED is
or becomes aware. If, by the end of such three (3) month period, LICENSEE has
not commenced such an action, UNEMED and/or INSTITUTIONS may prosecute such an
infringement at their own expense, controlling such action and retaining all
recoveries there from. With respect to any such infringement action prosecuted
by UNEMED and/or INSTITUTIONS in good faith, LICENSEE shall pay over to UNEMED
any payments (whether or not designated as "royalties") made by the alleged
infringer to LICENSEE under any existing or future sublicense authorizing
LICENSED PRODUCTS, up to the amount of UNEMED's and/or INSTITUTIONS'
unreimbursed litigation expenses (including, but not limited to, reasonable
attorneys' fees).

8.8 If a declaratory judgment action is brought naming LICENSEE as a defendant
and alleging invalidity of any of the PATENT RIGHTS, UNEMED and/or INSTITUTIONS
may elect to take over the sole defense of the action at its own expense.
LICENSEE shall cooperate fully with UNEMED and/or INSTITUTIONS in connection
with any such action.

                                   ARTICLE IX

                            TERMINATION OF AGREEMENT

9.1 This Agreement, unless terminated as provided herein, shall remain in effect
until the last patent or patent application in PATENT RIGHTS has expired or been
finally abandoned without the possibility of revival, or held invalid by a court
of competent jurisdiction.

9.2 UNEMED may terminate this Agreement as follows:

<PAGE>

     (a) If LICENSEE does not make a payment due hereunder and fails to cure
such non-payment (including the payment of interest in accordance with paragraph
5.4(e)) within forty-five (45) days after the date of notice in writing of such
non-payment by UNEMED.

     (b) If LICENSEE defaults in its obligations under paragraph 10.4(c) and
10.4(d) to procure and maintain insurance after a forty-five (45) day cure
period.

     (c) If, at any time after three years from the date of this Agreement,
UNEMED determines that the Agreement should be terminated pursuant to paragraph
3.2(d).

     (d) If LICENSEE shall become insolvent, shall make an assignment for the
benefit of creditors, or shall have a petition in bankruptcy filed for or
against it and has not been dismissed within one hundred eighty (180) days. Such
termination shall be effective immediately upon UNEMED giving written notice to
LICENSEE.

     (e) If an examination by UNEMED's accountant pursuant to Article VI shows
an underreporting or underpayment by LICENSEE in excess of 20% for any twelve
(12) month period.

     (f) If LICENSEE is convicted of a felony relating to the manufacture, use,
or sale of LICENSED PRODUCTS.

     (g) Except as provided in subparagraphs (a), (b), (c), (d), (e) and (f)
above, if LICENSEE defaults in the performance of any obligations under this
Agreement and the default has not been remedied within ninety (90) days after
the date of notice in writing of such default by UNEMED.

9.3 LICENSEE shall provide, in all sublicenses granted by it under this
Agreement, that LICENSEE's interest in such sublicenses shall become direct
licensees of UNEMED.

9.4 LICENSEE may terminate this Agreement by giving ninety (90) days advance
written notice of termination to UNEMED . Upon termination, LICENSEE shall
submit a final Royalty Report to UNEMED and any royalty payments and
unreimbursed patent expenses invoiced by UNEMED shall become immediately
payable.

9.5 Paragraphs 6.1, 6.2, 6.3, 7.1, 8.5, 9.4, 9.5, 10.2, 10.3,10.4, 10.6, 10.7,
and 10.8 of this Agreement shall survive termination.

                                    ARTICLE X

                                     GENERAL

<PAGE>

10.1 UNEMED does not warrant the validity of the PATENT RIGHTS licensed
hereunder and makes no representations whatsoever with regard to the scope of
the licensed PATENT RIGHTS or that such PATENT RIGHTS may be exploited by
LICENSEE, an AFFILIATE, or sublicensee without infringing other patents.

10.2 EXCEPT AS EXPRESSLY SET FORTH HEREIN, BOTH PARTIES EXPRESSLY DISCLAIM ANY
AND ALL IMPLIED OR EXPRESS WARRANTIES AND UNEMED MAKES NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE
PATENT RIGHTS, OR INFORMATION SUPPLIED BY UNEMED, LICENSED PROCESSES OR LICENSED
PRODUCTS CONTEMPLATED BY THIS AGREEMENT.

10.3 (a) LICENSEE shall indemnify, defend and hold harmless UNEMED and
INSTITUTIONS, their Regents, current or former directors, governing board
members, trustees, officers, faculty, medical and professional staff, employees,
students, and agents and their respective successors, heirs and assigns
(collectively, the "INDEMNITEES"), from and against any third party claim,
proceeding, demand, liability, cost, expense, damage, deficiency, loss or
obligation of any kind or nature (including, without limitation, reasonable
attorney's fees and other costs and expenses of litigation) (collectively,
"Claims"), based upon, arising out of the transfer, production, manufacture,
sale, use, lease, consumption, or advertisement of products, processes or
materials licensed by this Agreement or any other liabilities or obligations
otherwise relating to this Agreement, including without limitation any cause of
action relating to product liability concerning any product, process, or service
made, used or sold pursuant to any right or license granted under this
Agreement.

     (b) LICENSEE shall, at its own expense, provide attorneys reasonably
acceptable to UNEMED to defend against any actions brought or filed against any
Indemnitee hereunder with respect to the subject of indemnity contained herein,
whether or not such actions are rightfully brought.

     (c) Beginning at the time any such product, process or service is being
commercially distributed or sold (other than for the purpose of obtaining
regulatory approvals) by LICENSEE or by a sublicensee, AFFILIATE or agent of
LICENSEE, LICENSEE shall, at its sole cost and expense, procure and maintain
commercial general liability insurance in amounts not less than $2,000,000 per
incident and $2,000,000 annual aggregate and naming the Indemnitees as
additional insureds. During clinical trials of any such product, process or
service, LICENSEE shall, at its sole cost and expense, procure and maintain
commercial general liability insurance in such equal or lesser amount as UNEMED
shall require, naming the Indemnitees as additional insureds. Such commercial
general liability insurance shall provide (i) product liability coverage and
(ii) broad form contractual liability coverage for LICENSEE's indemnification
under this Agreement. If LICENSEE elects to self-insure all or part of the
limits described above (including deductibles or retentions which are in excess
of $250,000 annual aggregate) such self-

<PAGE>

insurance program must be acceptable to UNEMED in its sole discretion. The
minimum amounts of insurance coverage required shall not be construed to create
a limit of LICENSEE's liability with respect to its indemnification under this
Agreement.

     (d) LICENSEE shall provide UNEMED with written evidence of such insurance
upon request of UNEMED. LICENSEE shall provide UNEMED with written notice at
least fifteen (15) days prior to the cancellation, non-renewal or material
change in such insurance; if LICENSEE does not obtain replacement insurance
providing comparable coverage within such fifteen (15) day period, UNEMED shall
have the right to terminate this Agreement effective at the end of such fifteen
(15) day period without notice or any additional waiting periods.

     (e) LICENSEE shall maintain such commercial general liability insurance
beyond the expiration or termination of this Agreement during (i) the period
that any product, process, or service, relating to, or developed pursuant to,
this Agreement is being commercially distributed or sold by LICENSEE or by a
sublicensee, AFFILIATE or agent of LICENSEE and (ii) a reasonable period after
the period referred to in (e)(i) above which in no event shall be less than
fifteen (15) years.

10.4 LICENSEE shall not use name or insignia of UNEMED or INSTITUTIONS or any
adaptation of them, or the name of any of inventors in any advertising,
promotional or sales literature without the prior written approval of UNEMED.
Likewise, UNEMED or INSTITUTIONS shall not use the name or any adaptation of the
name of LICENSEE in any advertising, promotional or sales literature without
prior written approval of LICENSEE. Each party shall provide written approval or
denial within five (5) business days of such request.

10.5 Without the prior written approval of UNEMED in each instance, neither this
agreement nor the rights granted hereunder shall be transferred or assigned in
whole or in part by LICENSEE to any person whether voluntarily or involuntarily,
by operation of law or otherwise, except that the LICENSEE shall have the right
to assign this Agreement to another party without the consent of UNEMED in the
case of the sale, merger, change of control or transfer by LICENSEE of all, or
substantially all, of its assets relating to the LICENSED PRODUCT or LICENSED
PROCESS, to that party. This Agreement shall be binding upon the respective
successors, legal representatives and assignees of UNEMED and LICENSEE.

10.6 The interpretation and application of the provisions of this Agreement
shall be governed by the laws of the State of Nebraska.

10.7 LICENSEE shall comply with all applicable laws and regulations. In
particular, it is understood and acknowledged that the transfer of certain
commodities and technical data is subject to United States laws and regulations
controlling the export of such commodities and technical data, including all
Export Administration Regulations of the United States Department of Commerce.
These laws and regulations among other things, prohibit or require a license for
the export of certain types of technical data to certain specified countries.
LICENSEE hereby

<PAGE>

agrees and gives written assurance that it will comply with all United States
laws and regulations controlling the export of commodities and technical data,
that it will be solely responsible for any violation of such by LICENSEE or its
AFFILIATES or sublicensees, and that it will defend and hold UNEMED and
INSTITUTIONS harmless in the event of any legal action by a third party of any
nature occasioned by such violation.

10.8 LICENSEE agrees (i) to use commercially reasonable efforts to obtain all
regulatory approvals required for the manufacture and sale of LICENSED PRODUCTS
and LICENSED PROCESSES and (ii) to utilize appropriate patent marking on such
LICENSED PRODUCTS. LICENSEE also agrees to use commercially reasonable efforts
to register or record this Agreement as is required by law or regulation in any
country where the license is in effect.

10.9 Except as expressly set forth in this Agreement, nothing contained herein
shall be construed as a grant of a license in, to or regarding any materials,
information, technology, patent rights or other intellectual property rights of
LICENSEE or INSTITUTIONS.

10.10 Any notices to be given hereunder shall be sufficient if signed by the
party (or Party's attorney) giving it and either

(a)  delivered in person, or (b) mailed certified mail return receipt requested,
     or (c) faxed to other party if the sender has evidence of successful
     transmission and if the sender promptly sends the original by ordinary
     mail, in any event to the following addresses:

               If to LICENSEE:

                    ImaRx Therapeutics, Inc.
                    1635 E. 18th Street
                    Tucson, AZ 85719
                    Tel. 520-770-1259
                    Fax. 520-791-2437

               If to UNEMED:

                    UNEMED Corporation
                    986099 Nebraska Medical Center
                    Omaha, Nebraska, U.S. 69198-6099
                    Telephone Number 402-559-2468
                    Fax Number 402-559-2182

     By such notice either party may change their address for future notices.

     Notices delivered in person shall be deemed given on the date delivered.
Notices sent by fax shall be deemed given on the date faxed. Notices mailed
shall be deemed given on the date postmarked on the envelope.

10.11 Should a court of competent jurisdiction later hold any provision of this
Agreement to be

<PAGE>

invalid, illegal, or unenforceable, and such holding is not reversed on appeal,
it shall be considered severed from this Agreement. All other provisions, rights
and obligations shall continue without regard to the severed provision, provided
that the remaining provisions of this Agreement are in accordance with the
intention of the parties.

10.12 In the event of any controversy or claim arising out of or relating to any
provision of this Agreement or the breach thereof, the parties shall try to
settle such conflict amicably between themselves. This may include mediation,
arbitration, or any other procedures upon which the parties agree. Each party
agrees that, prior to resorting to litigation to resolve any dispute, it will
confer with other party to determine whether other procedures that are less
expensive or less time consuming can be adopted to resolve the dispute. Such
means of conflict resolution procedures shall be held in Omaha, Nebraska.
Notwithstanding the foregoing, either party may, without recourse to the above
mentioned conflict resolution procedure, assert against the other party a
third-party claim or cross-claim in any action brought by a third party, to
which the subject matter of this Agreement may be relevant.

10.13 This Agreement constitutes the entire understanding between the parties
and neither party shall be obligated by any condition or representation other
than those expressly stated herein or as may be subsequently agreed to by the
parties hereto in writing.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed
by their duly authorized representatives.

UNEMED CORPORATION                      IMARX THERAPEUTICS, INC.:

Thomas L. McDonald , Ph.D. President    Name: Jean Carlyle, CPA, MPA CFO

/s/ Thomas McDonald                     /s/ Jean Carlyle
-------------------------------------   ----------------------------------------
Signature                               Signature

Date 10-28-03                           Date 10-21-03

<PAGE>

                                   APPENDIX A

            Lipid Microbubble for Blood Clot Therapy Development Plan

                           Prepared for UNEMED 8/21/03

ImaRx has previously developed the lipid perfluorocarbon microbubble for
enhancing diagnostic ultrasound imaging. This product is FDA approved and
currently marketed by Bristol-Myer Squibb as Definity(R). ImaRx is developing
the therapeutic uses of this microbubble. While proof of concept may be
accomplished using the 'Definity' microbubble, ImaRx is in the process of
developing a new microbubble formulation that is specific for therapeutic use in
lysing blood clots (SonoLysis(TM)). The FDA would still need to approve the new
microbubble formulation and its new application to each disease state. In
addition to developing a superior microbubble formulation, an ultrasound device
is required for performing SonoLysis. We are currently engaging engineers to
develop new device and transducer elements that would be specific for the
particular disease state we seek to treat. Further experiments are required to
determine optimal ultrasound parameters for each disease state as the clots vary
in size, tissue depth and age, among other factors.

As a first clinical indication, ImaRx plans to conduct clinical trials for
dialysis graft that have become occluded due to blood clots. An IND has been
filed for this indication and clinical trials are planned to initiate prior to
the end of 2003. These phase I clinical trials are expected to enroll 24
patients and take 12-18 months to complete. For this indication, we propose to
use an off the shelf physical therapy ultrasound device. In the absence of
unexpected impediments and successful clinical trials, the product may be able
to be on the market in 5-7 years. Depending upon market conditions, other new
treatments available and previous clinical results, follow-on INDs are planned
to apply the SonoLysis technology to deep venous thrombosis, stroke, myocardial
infarction and possibly other diseases.

                                                                              16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]